Insider Buying: Artiva Biotherapeutics (NASDAQ:ARTV) Director Purchases $16,846.48 in Stock

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Director Ra Capital Management, L.P. bought 1,876 shares of Artiva Biotherapeutics stock in a transaction on Friday, June 26th. The stock was acquired at an average cost of $8.98 per share, for a total transaction of $16,846.48. Following the acquisition, the director owned 16,795,919 shares in the company, valued at approximately $150,827,352.62. This represents a 0.01% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Ra Capital Management, L.P. also recently made the following trade(s):

• On Thursday, June 25th, Ra Capital Management, L.P. bought 31,000 shares of Artiva Biotherapeutics stock. The stock was bought at an average cost of $8.88 per share, with a total value of $275,280.00.
• On Tuesday, June 16th, Ra Capital Management, L.P. bought 124,893 shares of Artiva Biotherapeutics stock. The stock was bought at an average price of $8.89 per share, for a total transaction of $1,110,298.77.
• On Monday, June 15th, Ra Capital Management, L.P. acquired 15,414 shares of Artiva Biotherapeutics stock. The shares were purchased at an average price of $8.99 per share, for a total transaction of $138,571.86.
• On Friday, June 12th, Ra Capital Management, L.P. acquired 391,019 shares of Artiva Biotherapeutics stock. The stock was purchased at an average cost of $8.57 per share, with a total value of $3,351,032.83.
• On Thursday, June 11th, Ra Capital Management, L.P. purchased 548,580 shares of Artiva Biotherapeutics stock. The shares were acquired at an average cost of $7.91 per share, with a total value of $4,339,267.80.
• On Wednesday, June 10th, Ra Capital Management, L.P. bought 103 shares of Artiva Biotherapeutics stock. The shares were bought at an average cost of $7.00 per share, with a total value of $721.00.
• On Tuesday, June 9th, Ra Capital Management, L.P. acquired 479,039 shares of Artiva Biotherapeutics stock. The stock was bought at an average cost of $6.91 per share, for a total transaction of $3,310,159.49.
• On Monday, May 11th, Ra Capital Management, L.P. purchased 6,510,416 shares of Artiva Biotherapeutics stock. The stock was purchased at an average price of $11.52 per share, for a total transaction of $74,999,992.32.

Artiva Biotherapeutics Trading Down 0.4%

ARTV stock traded down $0.04 during midday trading on Monday, hitting $9.58. The stock had a trading volume of 446,432 shares, compared to its average volume of 382,661. The firm has a market cap of $236.79 million, a P/E ratio of -2.71 and a beta of 2.40. Artiva Biotherapeutics, Inc. has a 1-year low of $1.48 and a 1-year high of $14.53. The business has a fifty day moving average price of $9.40 and a two-hundred day moving average price of $6.58.

Artiva Biotherapeutics (NASDAQ:ARTV) last announced its quarterly earnings data on Friday, May 8th. The company reported ($0.95) EPS for the quarter, missing the consensus estimate of ($0.88) by ($0.07). On average, equities analysts anticipate that Artiva Biotherapeutics, Inc. will post -2.45 EPS for the current year.

Institutional Trading of Artiva Biotherapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in ARTV. Marshall Wace LLP bought a new stake in shares of Artiva Biotherapeutics during the 2nd quarter worth $79,000. Qube Research & Technologies Ltd bought a new position in shares of Artiva Biotherapeutics during the second quarter valued at about $58,000. Jane Street Group LLC purchased a new position in Artiva Biotherapeutics in the 2nd quarter worth approximately $67,000. Bridgeway Capital Management LLC bought a new stake in Artiva Biotherapeutics during the 2nd quarter valued at $53,000. Finally, BNP Paribas Financial Markets raised its stake in shares of Artiva Biotherapeutics by 14,463.5% during the third quarter. BNP Paribas Financial Markets now owns 118,547 shares of the company’s stock valued at $340,000 after acquiring an additional 117,733 shares during the last quarter.

Wall Street Analyst Weigh In

ARTV has been the subject of several recent research reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Artiva Biotherapeutics in a report on Friday, April 24th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Artiva Biotherapeutics in a report on Tuesday, May 26th. HC Wainwright upped their target price on shares of Artiva Biotherapeutics from $15.00 to $35.00 and gave the stock a “buy” rating in a research note on Friday, May 8th. Wall Street Zen lowered shares of Artiva Biotherapeutics from a “hold” rating to a “sell” rating in a research note on Sunday, May 17th. Finally, Wedbush increased their target price on shares of Artiva Biotherapeutics from $23.00 to $40.00 and gave the company an “outperform” rating in a report on Monday, May 11th. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Artiva Biotherapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $39.00.

About Artiva Biotherapeutics

Artiva Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the development of allogeneic “off-the-shelf” cell therapies for cancer. The company’s proprietary platform leverages natural killer (NK) cells engineered to express chimeric antigen receptors (CARs) or other targeting modalities, with the goal of delivering potent anti-tumor activity while minimizing the safety and supply limitations associated with patient-derived (autologous) approaches.

Artiva’s pipeline includes multiple lead product candidates designed to address both hematologic malignancies and solid tumors.